Form 8-K
8-K — HARVARD BIOSCIENCE INC
Accession: 0001171843-26-007308
Filed: 2026-11-10
Period: 2026-11-10
CIK: 0001123494
SIC: 3826 (LABORATORY ANALYTICAL INSTRUMENTS)
Item: Results of Operations and Financial Condition
Item: Financial Statements and Exhibits
Documents
8-K — f8k_110726.htm (Primary)
EX-99.1 — EXHIBIT 99.1 (exh_991.htm)
GRAPHIC (logo.jpg)
XML — IDEA: XBRL DOCUMENT (R1.htm)
8-K — FORM 8-K
8-K (Primary)
Filename: f8k_110726.htm · Sequence: 1
false
0001123494
0001123494
2026-11-10
2026-11-10
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 10, 2026
HARVARD BIOSCIENCE, INC.
(Exact name of registrant as specified in its charter)
Delaware
001-33957
04-3306140
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
84 October Hill Road
Holliston, MA 01746
(Address of Principal Executive Offices) (Zip Code)
(508) 893-8999
(Registrant's telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $0.01 par value
HBIO
The NASDAQ Capital Market
Indicate by check mark whether the registrant is an emerging growth company as defined
in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2
of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected
not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section
13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On November 10, 2026, Harvard Bioscience, Inc. (the “Company”)
issued a press release announcing financial results for the three and nine months ended September 30, 2026, and the details of a related
conference call to be held at 8:00 AM ET on November 10, 2026. The press release is furnished as Exhibit 99.1 and incorporated herein
by reference.
The information in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached
hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange
Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under
the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit Number
Description
99.1
Press Release issued by Harvard Bioscience, Inc. on November 10, 2026
104
Cover Page Interactive Data File (embedded within the XBRL document)
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
HARVARD BIOSCIENCE, INC.
Date: November 10, 2026
By:
/s/ Mark Frost
Mark Frost
Chief Financial Officer
EX-99.1 — EXHIBIT 99.1
EX-99.1
Filename: exh_991.htm · Sequence: 2
Exhibit 99.1
Harvard Bioscience Announces Third Quarter 2026 Financial Results
· Third Quarter 2026 Revenue Growth of 8% Year Over Year to $22.2 Million
· Reaffirms Full Year 2026 Revenue Guidance of 3%-5% Year Over Year Growth
HOLLISTON, Mass., November 10, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience,
Inc. (Nasdaq: HBIO) (the “Company” or “Harvard Bioscience”) today announced financial results for the third quarter
ended September 30, 2026.
“We delivered our second consecutive quarter of strong year over
year growth with an 8% topline increase in the third quarter,” said John Duke, President and Chief Executive Officer. “We
saw solid double-digit revenue growth to CROs and customers in China, driven by sales of our products for organoids, respiratory, and
fluidics products. Our revamped sales and marketing teams are delivering encouraging results, and Project Viking remains on track for
completion by the end of the first quarter in 2027. Looking ahead, our sales momentum, continued New Product Innovation (NPI) adoption,
and progress on key initiatives give us confidence in the trajectory of the business.”
Third Quarter 2026 Results
For the third quarter of 2026, the Company reported revenues of $22.2 million
compared to $20.6 million in the third quarter of 2025. Revenue for the third quarter of 2026 included an unfavorable impact from foreign
currency exchange rates of less than 1%, using a constant currency basis. Gross profit for the third quarter of 2026 was $12.3 million
compared to $12.0 million in the third quarter of 2025. Gross margin for the third quarter of 2026 was 55.4%, compared to 58.4% in the
third quarter of 2025.
Adjusted gross profit and adjusted gross margin for the third
quarter of 2026 were $12.7 million and 57.1%, respectively, compared with $12.2 million and 59.2% in the same period of the prior year.
Net loss for the third quarter of 2026 was $(2.6) million, compared
to a net loss of $(1.2) million in the third quarter of 2025. Adjusted EBITDA for the third quarter of 2026 was $1.8 million compared
to $2.0 million in the third quarter of the prior year. Cash (used in) provided by operations was $(0.2) million during the three months
ended September 30, 2026 compared to $1.0 million in the same period of the prior year.
Nine Months Ended September 30, 2026 Results
For the nine months ended September 30, 2026, the Company reported
revenues of $65.7 million, compared to $62.8 million in the same period of the prior year. Revenue for the nine months ended September
30, 2026, included a favorable impact from foreign currency exchange rates of approximately 1.2%, using a constant currency basis. Gross
profit was $37.2 million for the first nine months of 2026 compared to $35.7 million in the same period of the prior year. Gross margin
for the nine months ended September 30, 2026, was 56.6% compared with 56.9% in the same period of the prior year.
Adjusted gross profit and adjusted gross margin for the nine
months ended September 30, 2026, were $38.0 million and 57.9%, respectively, compared with $36.3 million and 57.7% in the same period
of the prior year.
Net loss for the nine months ended September 30, 2026, was $(9.0)
million compared to a net loss of $(53.9) million in the same period of the prior year, primarily due to goodwill impairment in the first
quarter of 2025 of $48.0 million. Adjusted EBITDA for the nine months ended September 30, 2026, was $4.2 million, compared to adjusted
EBITDA of $4.3 million for the same period of the prior year. Cash (used in) provided by operations was $(0.6) million during the nine
months ended September 30, 2026 compared to $6.8 million in the same period of the prior year.
This press release includes certain financial information presented
on an adjusted, or non-GAAP, basis. For additional information on the non-GAAP financial measures included in this press release, see
“Use of Non-GAAP Financial Information” and “Reconciliation of GAAP to Non-GAAP Financial Measures” below.
Fourth Quarter 2026 Guidance
The Company’s fourth quarter outlook at the midpoint of
the guidance ranges reflects expected year-over-year revenue growth driven by ongoing demand across Cellular & Molecular Technology
(CMT) and NPI platforms, sequential gross margin expansion, and improving year-over-year profitability on an adjusted EBITDA basis. The
Company expects:
· Revenue between $23.7 million and $25.5 million
· Adjusted gross margin between 59% and 61%
· Adjusted EBITDA between $3.8 million and $4.2 million
Full Year 2026 Guidance
The Company is reaffirming its full-year 2026 revenue and gross
margin guidance while updating its full-year adjusted EBITDA target to account for higher-than-expected sales of certain lower-margin
CMT products and higher revenue contribution from distribution channels and China. The Company now expects:
· Revenue growth between 3% and 5%
· Adjusted gross margin between 57% and 59%
· Adjusted EBITDA between (1%) and 4% growth
Webcast and Conference Call Details
In conjunction with this announcement, Harvard Bioscience will
be hosting a conference call and webcast today at 8:00 a.m. Eastern Time. A presentation that will be referenced during the webcast will
be posted to the Company’s Investor Relations website shortly before the webcast begins.
Analysts who would like to join the call and ask
a question must register here. Once registered, you will receive the dial-in numbers and a unique PIN number.
Participants who would like to join the audio-only
webcast should go to our events and presentations on the investor website here.
Use of Non-GAAP Financial Information
In this press release we have included non-GAAP financial information,
including one or more of adjusted operating income (loss), adjusted operating margin, adjusted gross margin, adjusted net income (loss),
adjusted EBITDA, adjusted EBITDA margin, diluted adjusted earnings (loss) per share, net debt, adjusted gross profit, and non-GAAP revenue
on a constant currency basis. We believe that this non-GAAP financial information provides investors with an enhanced understanding of
the underlying operations of our business. For the periods presented, these non-GAAP financial measures have excluded certain expenses
and income resulting from items that we do not believe are reflective of the underlying operations of the business. Items excluded include
stock-based compensation, amortization of intangibles related to acquisitions, Non-GAAP restructuring related charges, other operating
expenses, goodwill impairment, interest and other expense, net, income taxes, and the tax impact of reconciling items. Management believes
that this non-GAAP financial information is important in comparing current results with prior period results and is useful to investors
and financial analysts in assessing the Company’s operating performance.
Historical non-GAAP financial information included herein is accompanied
by a reconciliation to the nearest corresponding GAAP measure, which is included below. In addition, the forward-looking Adjusted gross
margin and Adjusted EBITDA guidance for the fourth quarter of 2026 and full-year 2026 excludes potential charges or gains that may be
recorded during the fiscal year, including among other things, restructuring and reorganization expenses, and non-GAAP restructuring related
expenses. The Company has not attempted to provide reconciliations of such forward-looking non-GAAP earnings guidance to the comparable
GAAP measure, as permitted by Item 10(e)(1)(i)(B) of Regulation S-K, because the impact and timing of these potential charges or gains
is inherently uncertain and difficult to predict and is unavailable without unreasonable efforts. In addition, the Company believes such
reconciliations would imply a degree of precision and certainty that could be misleading to investors. Such items could have a substantial
impact on GAAP measures of the Company’s financial performance.
The non-GAAP financial information provided in this press release
should be considered in addition to, not as a substitute for, the financial information provided and presented in accordance with GAAP
and may be different from other companies’ non-GAAP financial information.
About Harvard Bioscience
Harvard Bioscience, Inc. is a leading developer, manufacturer and
seller of technologies, products and services that enable fundamental advances in life science applications, including research, drug
and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. Our customers range from renowned
academic institutions and government laboratories to the world’s leading pharmaceutical, biotechnology and contract research organizations.
With operations in the United States, Europe, and China, we sell through a combination of direct and distribution channels to customers
around the world.
For more information, please visit our website
at www.harvardbioscience.com.
Forward-Looking Statements
This document contains forward-looking statements within the meaning of
the federal securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified
by the use of words such as “may,” “will,” “expect,” “plan,” “anticipate,”
“estimate,” “intend,” “believe” and similar expressions or statements that do not relate to historical
matters. Forward-looking statements include, but are not limited to, information concerning expected future financial and operational
performance including revenues, adjusted gross margin, adjusted EBITDA, gross margin, cash and debt position, balance sheet, growth, adoption
and the introduction of new products, the strength of the Company’s market position, business model and anticipated macroeconomic
conditions. Forward-looking statements do not guarantee future performance and involve known and unknown uncertainties, risks, assumptions,
and contingencies, many of which are outside the Company’s control. Risks and other factors that could cause the Company’s
actual results to differ materially from those described in its forward-looking statements include those described in the “Risk
Factors” section of the Company’s most recently filed Annual Report on Form 10-K, as well as in the Company’s other
filings with the Securities and Exchange Commission. Forward-looking statements are based on the Company’s expectations and assumptions
as of the date of this document. Except as required by law, the Company assumes no obligation to update forward-looking statements to
reflect any change in expectations, even as new information becomes available.
Investor Inquiries:
Mark Frost
Chief Financial Officer
(508) 893-3120
investors@harvardbioscience.com
HARVARD BIOSCIENCE, INC.
Condensed Consolidated Statements Of Operations
(Unaudited, in thousands, except
per share data)
Three Months Ended September 30,
Nine Months Ended September 30,
2026
2025
2026
2025
Revenues
$ 22,196
$ 20,591
$ 65,678
$ 62,815
Cost of revenues
9,889
8,570
28,497
27,077
Gross profit
12,307
12,021
37,181
35,738
Sales and marketing expenses
5,420
4,613
16,155
14,123
General and administrative expenses
4,756
4,176
14,075
13,623
Research and development expenses
2,258
2,132
7,037
6,642
Amortization of intangible assets
365
855
2,005
3,177
Goodwill impairment
-
-
-
47,951
Other operating expenses
658
48
1,211
512
Total operating expenses
13,457
11,824
40,483
86,028
Operating (loss) income
(1,150 )
197
(3,302 )
(50,290 )
Other income (expense):
Interest expense
(1,783 )
(1,323 )
(5,304 )
(3,257 )
Other income (expense), net
238
(8 )
(292 )
(635 )
Total other expense
(1,545 )
(1,331 )
(5,596 )
(3,892 )
Loss before income taxes
(2,695 )
(1,134 )
(8,898 )
(54,182 )
Income tax (benefit) expense
(72 )
97
59
(329 )
Net loss
$ (2,623 )
$ (1,231 )
$ (8,957 )
$ (53,853 )
Loss per share:
Basic and diluted loss per share *
$ (0.58 )
$ (0.28 )
$ (1.99 )
$ (12.15 )
Weighted-average common shares:
Basic and diluted *
4,561
4,456
4,500
4,432
* Retroactively presented to reflect 1-for-10 reverse
stock split effective on March 13, 2026.
HARVARD BIOSCIENCE, INC.
Condensed Consolidated Balance Sheets
(Unaudited, in thousands, except share and per share data)
September 30, 2026
December 31, 2025
Assets
Cash and cash equivalents
$ 4,856
$ 8,614
Accounts receivable, net
14,912
16,043
Inventories
23,491
20,805
Other current assets
2,718
2,763
Total current assets
45,977
48,225
Property, plant and equipment
5,399
4,787
Goodwill and other intangibles
15,481
17,198
Other long-term assets
8,442
9,861
Total assets
$ 75,299
$ 80,071
Liabilities and Stockholders' Equity
Other current liabilities
26,127
21,960
Total current liabilities
26,127
21,960
Long-term debt, net
37,153
35,870
Other long-term liabilities
6,914
8,507
Stockholders’ equity
5,105
13,734
Total liabilities and stockholders’ equity
$ 75,299
$ 80,071
HARVARD BIOSCIENCE, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited, in thousands)
Nine Months Ended
September 30, 2026
September 30, 2025
Cash flows from operating activities:
Net loss
$ (8,957 )
$ (53,853 )
Adjustments to operating cash flows
6,083
54,087
Changes in operating assets and liabilities
2,289
6,591
Net cash (used in) provided by operating activities
(585 )
6,825
Cash flows from investing activities:
Additions to property, plant and equipment
(2,041 )
(809 )
Acquisition of intangible assets
(838 )
(455 )
Net cash used in investing activities
(2,879 )
(1,264 )
Cash flows from financing activities:
Repayment of term debt
-
(3,000 )
Payment of debt issuance costs
(131 )
(687 )
Proceeds from exercise of warrants and stock purchase plan
150
46
Taxes paid related to net share settlement of equity awards
(111 )
(99 )
Net cash used in financing activities
(92 )
(3,740 )
Effect of exchange rate changes on cash and cash equivalents
(202 )
888
(Decrease) increase in cash and cash equivalents
(3,758 )
2,709
Cash and cash equivalents at the beginning of period
8,614
4,108
Cash and cash equivalents at the end of period
$ 4,856
$ 6,817
HARVARD BIOSCIENCE, INC.
Reconciliation of GAAP to Non-GAAP Financial Measures (unaudited)
(in thousands, except per share
data and percentages)
Three Months Ended
Nine Months Ended
September 30, 2026
September 30, 2025
September 30, 2026
September 30, 2025
GAAP operating (loss) income
$ (1,150 )
$ 197
$ (3,302 )
$ (50,290 )
Stock-based compensation
436
324
1,073
1,396
Acquired asset amortization
365
855
2,005
3,177
Goodwill impairment
-
-
-
47,951
Other operating expenses (1)
658
48
1,211
512
Other adjustments (2)
864
93
1,535
135
Adjusted operating income
$ 1,173
$ 1,517
$ 2,522
$ 2,881
Operating margin
(5.2 )%
1.0 %
(5.0 )%
(80.1 )%
Adjusted operating margin
5.3 %
7.4 %
3.8 %
4.6 %
GAAP net loss
$ (2,623 )
$ (1,231 )
$ (8,957 )
$ (53,853 )
Stock-based compensation
436
324
1,073
1,396
Acquired asset amortization
365
855
2,005
3,177
Goodwill impairment
-
-
-
47,951
Other operating expenses (1)
658
48
1,211
512
Other adjustments (2)
864
93
1,535
135
Income taxes
12
(250 )
727
(266 )
Adjusted net loss
(288 )
(161 )
(2,406 )
(948 )
Depreciation & amortization
588
468
1,669
1,417
Interest and Other income (expense), net (3)
1,545
1,331
5,596
3,892
Adjusted income taxes (4)
(84 )
347
(668 )
(63 )
Adjusted EBITDA
$ 1,761
$ 1,985
$ 4,191
$ 4,298
Adjusted EBITDA margin
7.9 %
9.6 %
6.4 %
6.8 %
Diluted loss per share (GAAP)
$ (0.58 )
$ (0.28 )
$ (1.99 )
$ (12.15 )
Diluted adjusted loss per share
$ (0.06 )
$ (0.04 )
$ (0.53 )
$ (0.21 )
Weighted-average common shares:
Diluted GAAP *
4,561
4,456
4,500
4,432
Diluted Adjusted *
4,561
4,456
4,500
4,432
September 30,
2026
2025
Debt, including unamortized deferred financing costs
$ 37,153
$ 33,967
Unamortized deferred financing costs
2,847
383
Cash and cash equivalents
(4,856 )
(6,817 )
Net debt
$ 35,144
$ 27,533
* Retroactively presented to reflect 1-for-10 reverse stock split effective on March 13, 2026.
(1) Other operating expenses for the three months ended September 30, 2026 includes $658 thousand of restructuring-related charges compared to $48 thousand of restructuring-related charges for the three months ended September 30, 2025. Other operating expenses for the nine months ended September 30, 2026 includes $1.2 million of restructuring-related charges compared to $171 thousand of restructuring-related charges and $341 thousand related to ERTC Fees for the nine months ended September 30, 2025.
(2) Other adjustments for the three months ended September 30, 2026 includes
$864 thousand of Non-GAAP restructuring-related charges compared to $93 thousand of Non-GAAP restructuring-related charges for the three
months ended September 30, 2025. Other adjustments expenses for the nine months ended September 30, 2026 includes $1.5 million of Non-GAAP
restructuring-related charges compared to $135 thousand of Non-GAAP restructuring-related charges for the nine months ended September
30, 2025.
(3) Interest expense for the three months ended September 30, 2026 was $1.8 million compared to $1.3 million for the three months
ended September 30, 2025. Interest expense for the nine months ended September 30, 2026 was $5.3 million compared to $3.3 million for
the nine months ended September 30, 2025.
(4) Adjusted income taxes includes the tax effect of adjusting
for the reconciling items using the tax rates in the jurisdictions in which the reconciling items arise.
HARVARD BIOSCIENCE, INC.
Reconciliation of GAAP to Non-GAAP Financial Measures (unaudited)
(in thousands, except per share data and percentages)
Three Months Ended September 30,
Nine Months Ended September 30,
Non-GAAP revenue on a constant currency basis
2026
2025
Growth Rates
2026
2025
Growth Rates
Total revenues
$ 22,196
$ 20,591
7.8 %
65,678
62,815
4.6 %
Effects of foreign currency rate fluctuations
7
-
(723 )
Revenue on a constant currency basis
$ 22,203
$ 20,591
7.8 %
64,955
62,815
3.4 %
Three Months Ended September 30,
Nine Months Ended September 30,
Non-GAAP Gross Profit and Non-GAAP Gross Margin
2026
2025
2026
2025
Amount
Margin
Amount
Margin
Amount
Margin
Amount
Margin
(in thousands)
Gross profit
$ 12,307
55.4 %
$ 12,021
58.4 %
$ 37,181
56.6 %
$ 35,738
56.9 %
Adjustments:
Stock-based compensation expense - cost of sales
13
0.1 %
18
0.1 %
34
0.1 %
79
0.1 %
Depreciation and amortization - cost of sales
201
0.9 %
156
0.8 %
598
0.9 %
440
0.7 %
Other adjustments - cost of sales (1)
143
0.6 %
-
0.0 %
188
0.3 %
-
0.0 %
Non-GAAP gross profit
$ 12,664
57.1 %
$ 12,195
59.2 %
$ 38,001
57.9 %
$ 36,257
57.7 %
(1) Other adjustments - cost of sales for the three months ended September 30, 2026 includes $143 thousand of Non-GAAP restructuring-related charges. Other adjustments - cost of sales for the nine months ended September 30, 2026 includes $188 thousand of Non-GAAP restructuring-related charges.
GRAPHIC
GRAPHIC
Filename: logo.jpg · Sequence: 6
Binary file (7010 bytes)
Download logo.jpg
XML — IDEA: XBRL DOCUMENT
XML
Filename: R1.htm · Sequence: 8
v3.26.3
Cover
Nov. 10, 2026
Cover [Abstract]
Document Type
8-K
Amendment Flag
false
Document Period End Date
Nov. 10, 2026
Entity File Number
001-33957
Entity Registrant Name
HARVARD BIOSCIENCE, INC.
Entity Central Index Key
0001123494
Entity Tax Identification Number
04-3306140
Entity Incorporation, State or Country Code
DE
Entity Address, Address Line One
84 October Hill Road
Entity Address, City or Town
Holliston
Entity Address, State or Province
MA
Entity Address, Postal Zip Code
01746
City Area Code
(508)
Local Phone Number
893-8999
Written Communications
false
Soliciting Material
false
Pre-commencement Tender Offer
false
Pre-commencement Issuer Tender Offer
false
Title of 12(b) Security
Common Stock, $0.01 par value
Trading Symbol
HBIO
Security Exchange Name
NASDAQ
Entity Emerging Growth Company
false
X
- Definition
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
No definition available.
+ Details
Name:
dei_AmendmentFlag
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Area code of city
+ References
No definition available.
+ Details
Name:
dei_CityAreaCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Cover page.
+ References
No definition available.
+ Details
Name:
dei_CoverAbstract
Namespace Prefix:
dei_
Data Type:
xbrli:stringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
No definition available.
+ Details
Name:
dei_DocumentPeriodEndDate
Namespace Prefix:
dei_
Data Type:
xbrli:dateItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details
Name:
dei_DocumentType
Namespace Prefix:
dei_
Data Type:
dei:submissionTypeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Address Line 1 such as Attn, Building Name, Street Name
+ References
No definition available.
+ Details
Name:
dei_EntityAddressAddressLine1
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the City or Town
+ References
No definition available.
+ Details
Name:
dei_EntityAddressCityOrTown
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Code for the postal or zip code
+ References
No definition available.
+ Details
Name:
dei_EntityAddressPostalZipCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the state or province.
+ References
No definition available.
+ Details
Name:
dei_EntityAddressStateOrProvince
Namespace Prefix:
dei_
Data Type:
dei:stateOrProvinceItemType
Balance Type:
na
Period Type:
duration
X
- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityCentralIndexKey
Namespace Prefix:
dei_
Data Type:
dei:centralIndexKeyItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityEmergingGrowthCompany
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
No definition available.
+ Details
Name:
dei_EntityFileNumber
Namespace Prefix:
dei_
Data Type:
dei:fileNumberItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Two-character EDGAR code representing the state or country of incorporation.
+ References
No definition available.
+ Details
Name:
dei_EntityIncorporationStateCountryCode
Namespace Prefix:
dei_
Data Type:
dei:edgarStateCountryItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityRegistrantName
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityTaxIdentificationNumber
Namespace Prefix:
dei_
Data Type:
dei:employerIdItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Local phone number for entity.
+ References
No definition available.
+ Details
Name:
dei_LocalPhoneNumber
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
+ Details
Name:
dei_PreCommencementIssuerTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
+ Details
Name:
dei_PreCommencementTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Title of a 12(b) registered security.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
+ Details
Name:
dei_Security12bTitle
Namespace Prefix:
dei_
Data Type:
dei:securityTitleItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the Exchange on which a security is registered.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
+ Details
Name:
dei_SecurityExchangeName
Namespace Prefix:
dei_
Data Type:
dei:edgarExchangeCodeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14a
-Subsection 12
+ Details
Name:
dei_SolicitingMaterial
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details
Name:
dei_TradingSymbol
Namespace Prefix:
dei_
Data Type:
dei:tradingSymbolItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
+ Details
Name:
dei_WrittenCommunications
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration